L’Oréal’s venture capital fund ‘Bold’ has led a funding round for Debut, a synthetic biology company spearheading the creation of innovative and novel high-performing active ingredients in beauty.

Debut raised $34M in a Series B in a funding round. Participating investors include Fine Structure Ventures, Material Impact, GS Futures, Cavallo Ventures, Cultivian Sandbox Ventures, ACVC Partners, and others. 

Debut’s $22.6M Series A in August 2021, led by Material Impact, helped scale its unique and unprecedented ingredient development model, establish its in-house brand incubator, and grow into its 26,000-square-foot facility in San Diego. 

As part of the strategic partnership with Bold, Debut will develop a wide variety of novel ingredients and beauty and personal care products using its proprietary cell-free and biotechnology model. Debut aims to accelerate the commercialization of this technology across the entire beauty industry.

Debut is the only player in the biotech space with full vertical integration capabilities incorporating ingredient discovery, finished clinically-backed scalable ingredients and brands on shelf, all delivered at unprecedented speed.

The Series B financing and partnership with BOLD will equip Debut with the resources to quickly establish this new benchmark in the industry. 

Joshua Britton, Ph.D., founder and CEO of Debut, says, “Debut exists to set a new standard in beauty by developing novel active ingredients that herald a new era with regard to performance, sustainability, scalability and cost…Everyday, we are leveraging our team’s groundbreaking technology, scientific research and unbridled creativity to lead the biological revolution that will transform beauty as we know it. We harness synthetic biology to create novel and higher-performing ingredients that are not accessible by other means in order to advance product benefits and target unmet consumer needs.”

Barbara Lavernos, Deputy Chief Executive Officer in charge of Research, Innovation and Technology, at L’Oréal, adds, “Debut addresses one of the beauty world’s fundamental challenges: driving innovation without the resource-intensity and environmental impact that comes with relying on traditional manufacturing alone.”

Lavernos continues, “Cell-free biomanufacturing is not science fiction: it is here. We could not be more excited to be the first beauty leader to invest in Debut and partner with them to create stand-out active beauty innovations while protecting the planet’s resources.”

Debut’s proprietary Bio2Consumer™ platform spans ingredient discovery, cell-free, biofermentation, formulation, clinical trials and brand creation. The platform utilizes cell-free and advanced fermentation approaches such as continuous biomanufacturing to overcome the limitations of traditional methods, dramatically reducing the need for space, water, and expensive and unsustainable inputs.

In addition to producing rare, high-value and novel compounds, Debut’s technology also improves traditional ingredient manufacturing. The platform comprises a proprietary database of over 3.8 million pre-clinical data points to find and discover new ingredients that address beauty consumer needs. By overcoming the limitations of cell-based fermentation, Debut can produce high-value ingredients rapidly and more sustainably. 

Debut’s portfolio of ingredients are both natural and lab-made. “What science allows us to do is understand how nature makes it, and then translate that to an industrially scalable system to provide the exact same molecules that are found in trace amounts in nature using synthetic biology,” adds Britton.